New tool helps nasal cancer patients voice their satisfaction
NCT ID NCT07257094
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire, which measures how patients feel about their appearance, quality of life, and side effects after nasal reconstruction or prosthetic rehabilitation following nasal skin cancer surgery. About 346 adults who had surgery 4 months to 3 years ago will participate. The goal is to provide a reliable tool for doctors to better understand patient satisfaction and improve care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 346 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients / Controls
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
PATIENTS Inclusion Criteria * Age ≥ 18 years * Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago * Patient informed of the study and not opposed to participation Exclusion Criteria * Patient under anticoagulant or antiplatelet therapy Non-French-speaking patient * Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity * Patient unlikely to cooperate with the study and/or poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment) * Pregnant or breastfeeding woman CONTROL Inclusion Criteria * Age ≥ 65 years * Subject informed and not opposed to participating in the study * Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows: * No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months); * No severe chronic respiratory disease (no stage III-IV COPD, no prolonged oxygen therapy); * No uncontrolled diabetes or associated severe complications; * No active immunosuppressive diseases or high-dose immunosuppressive treatment; * No unstable or severe facial dermatological conditions; * No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion). Exclusion Criteria * Non-English speaking subject * Subject under guardianship or legal protection, legally incompetent or with limited legal capacity * Subject unlikely to cooperate in the study and/or anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders) * Pregnant or breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
9 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Caen
NOT_YET_RECRUITINGCaen, 14000, France
-
CHU Toulouse
NOT_YET_RECRUITINGToulouse, 31400, France
-
Centre Antoine Lacassagne
RECRUITINGNice, 06000, France
-
HNIA Toulon
RECRUITINGToulon, 83000, France
-
Hopital Novo
RECRUITINGPontoise, 95300, France
-
Hôpital Bichat (APHP)
NOT_YET_RECRUITINGParis, 75018, France
-
Hôpital Lariboisière (AP-HP)
NOT_YET_RECRUITINGParis, 75010, France
-
Institut Curie
NOT_YET_RECRUITINGParis, 75005, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94800, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive antibody aims to light up hidden solid tumors
- Can a two-drug combo outsmart resistant lung cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Could your workout history affect your Cancer's genes?